PMID- 20683633
OWN - NLM
STAT- MEDLINE
DCOM- 20110407
LR  - 20221207
IS  - 1439-7609 (Electronic)
IS  - 1439-7595 (Linking)
VI  - 20
IP  - 6
DP  - 2010 Dec
TI  - Better short-term clinical response to etanercept in Chinese than Caucasian 
      patients with active ankylosing spondylitis.
PG  - 580-7
LID - 10.1007/s10165-010-0334-2 [doi]
AB  - Tumor necrosis factor-alpha (TNF-alpha) inhibitors including etanercept have been 
      demonstrated to be very effective in severe ankylosing spondylitis (AS) in 
      Caucasian patients. However, clinical efficacy of etanercept to treat active AS 
      in Chinese patients has not been reported. In this study, a prospective, 
      open-label trial of etanercept (25 mg BIW), involving 46 AS patients from 16 
      medical centers of Taiwan, was conducted. Questionnaire was utilized to record 
      demographic data and clinical parameters, including Bath AS Disease Activity 
      Index (BASDAI), Bath AS Functional Index (BASFI), Bath AS Global Index (BASGI), 
      Assessment in Ankylosing Spondylitis (ASAS) 20, 50, and 70, and others, before 
      and at different time intervals after etanercept treatment. Laboratory tests 
      including blood chemistry, hematology, urine analysis, erythrocyte sedimentation 
      rate (ESR), and C-reactive protein (CRP) were done at baseline and at weeks 4, 8, 
      and 12. In this 12-week study, etanercept demonstrated rapid and significant 
      improvement in the ASAS20 response criteria (91.3%), at as early as 2 weeks of 
      therapy (71.3%). Partial remission of AS was achieved in 49.3% of patients after 
      12 weeks of treatment. Disease activity (BASDAI) and function (BASFI) were also 
      significantly improved after 12 weeks etanercept treatment (p < 0.0001 and p < 
      0.0001, respectively). In addition, significant increase of chest expansion (2.77 
      +/- 1.69 cm versus 3.56 +/- 1.82 cm, p = 0.0004) and lumbar flexion (2.11 +/- 2.76 cm 
      versus 2.58 +/- 3.42 cm, p = 0.0075) and significant reduction of occiput-to-wall 
      distance (6.59 +/- 7.14 cm versus 5.32 +/- 6.65 cm, p = 0.0006) were also 
      demonstrated. Both ESR and CRP declined significantly after patients were treated 
      with etanercept. There were no severe adverse effects during the treatment 
      period. Etanercept is generally safe, well tolerated, and effective in Chinese 
      patients with severe AS. Clinical efficacy, including partial remission and 
      BASDAI, is even better in Chinese than in Caucasian patients. Further study is 
      required to assess long-term efficacy and safety in Chinese patients with AS.
FAU - Chou, Chung-Tei
AU  - Chou CT
AD  - Division of Allergy-Immunology-Rheumatology, Veterans General Hospital, No. 201, 
      Sec. 2, Shih-Pai Road, Shih-Pai, Taipei, 11217, Taiwan. ctchou@vghtpe.gov.tw
FAU - Tsai, Chang-Youh
AU  - Tsai CY
FAU - Liang, Tung-Hua
AU  - Liang TH
FAU - Chang, Te-Ming
AU  - Chang TM
FAU - Lai, Chen-Hung
AU  - Lai CH
FAU - Wei, Cheng-Chung
AU  - Wei CC
FAU - Chen, Kun-Hung
AU  - Chen KH
FAU - Lin, Shih-Chang
AU  - Lin SC
FAU - Yu, Chia-Li
AU  - Yu CL
FAU - Liou, Lieh-Bang
AU  - Liou LB
FAU - Luo, Shue-Fen
AU  - Luo SF
FAU - Lee, Chyou-Shen
AU  - Lee CS
FAU - Hsue, Yin-Tzu
AU  - Hsue YT
FAU - Huang, Chung-Ming
AU  - Huang CM
FAU - Chen, Jiunn-Hong
AU  - Chen JH
FAU - Lai, Ning-Sheng
AU  - Lai NS
FAU - Cheng, He-Hsiung
AU  - Cheng HH
FAU - Cheng, Tien-Tsai
AU  - Cheng TT
FAU - Lai, Han-Ming
AU  - Lai HM
FAU - Tsai, Wen-Chan
AU  - Tsai WC
FAU - Yen, Jeng-Hsien
AU  - Yen JH
FAU - Lu, Ling-Ying
AU  - Lu LY
FAU - Chang, Chung-Pei
AU  - Chang CP
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
DEP - 20100804
PL  - England
TA  - Mod Rheumatol
JT  - Modern rheumatology
JID - 100959226
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Adult
MH  - Antirheumatic Agents/*therapeutic use
MH  - *Asian People
MH  - Etanercept
MH  - Female
MH  - Health Status
MH  - Humans
MH  - Immunoglobulin G/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Receptors, Tumor Necrosis Factor/*therapeutic use
MH  - Recovery of Function
MH  - Remission Induction
MH  - Severity of Illness Index
MH  - Spondylitis, Ankylosing/*drug therapy/*ethnology/physiopathology
MH  - Treatment Outcome
MH  - *White People
MH  - Young Adult
EDAT- 2010/08/05 06:00
MHDA- 2011/04/08 06:00
CRDT- 2010/08/05 06:00
PHST- 2010/01/13 00:00 [received]
PHST- 2010/05/28 00:00 [accepted]
PHST- 2010/08/05 06:00 [entrez]
PHST- 2010/08/05 06:00 [pubmed]
PHST- 2011/04/08 06:00 [medline]
AID - 10.1007/s10165-010-0334-2 [doi]
PST - ppublish
SO  - Mod Rheumatol. 2010 Dec;20(6):580-7. doi: 10.1007/s10165-010-0334-2. Epub 2010 
      Aug 4.